Biopharma buffers help in pH regulation and maintaining the stability of biomolecules such as proteins, DNA, and other biopharmaceutical products. Biopharma buffers are used in various stages of biomanufacturing processes including cell cultivation, purification, formulation, and storage. Increase in production of monoclonal antibody therapies and recombinant proteins have fueled demand for biopharma buffers. The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market key trends:

The increased demand for biologic drugs such as monoclonal antibodies for treatment of various chronic diseases is a key trend driving the growth of the biopharma buffer market. Monoclonal antibodies production has significantly increased over the past few years. According to International Federation of Pharmaceutical Manufacturers & Associations, monoclonal antibodies now account for over 50% of the therapeutic medicine currently in pipeline. Their production involves multistage processes requiring buffers at various stages for optimal functioning of enzymes and reactions. This growing demand for monoclonal antibodies has significantly driven the growth of global biopharma buffer market over the past few years and the trend is expected to continue during the forecast period.

Here is the segment analysis and key takeaways without mentioning market size, CAGR or conclusion for the given Biopharma Buffer Market:

Segment Analysis

The global Biopharma buffer market is dominated by phosphate buffer segment. Phosphate buffer solutions are commonly used to maintain the pH of biopharmaceutical formulations and solutions within optimal ranges. Phosphate buffers are capable of maintaining pH levels between 5.8-8.0, which covers the physiological pH range required for most biopharmaceutical products. They are stable, non-toxic and have good buffering capacity, which makes them suitable for widespread use in biologics manufacturing.

Key Takeaways

The Global Biopharma Buffer Market Size is expected to witness high growth over the forecast period of 2023 to 2030.

Regional analysis: North America currently dominates the global market and is expected to continue its dominance during the forecast period. High biopharmaceutical R&D spending, presence of key market players and increasing demand for generic drugs drive the growth of the Biopharma buffer market in North America.

Key players: operating in the Biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., BD, Promega Corporation. Companies are focusing on new product launches and expansion strategies to gain market share. For instance, in 2022, Thermo Fisher Scientific expanded its bioprocessing product portfolio with the acquisition of Pharmingen.

Get More Insights Here

https://www.newsstatix.com/biopharma-buffer-market-industry-insights-trends-biopharma-buffer-market/